Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with plasma HCV RNA level \>10,000 IU/L for the two groups.~* Treatment-experienced patients in group 1 were those who had previously failed treatment with classical peg-IFN/RBV therapy.~* Treatment-experienced patients in group 2 were those who had previously failed treatment with SOF/RBV~Exclusion Criteria:~* coinfected with hepatitis B virus or human immunodeficiency virus infection,~* any cause of liver disease other than HCV GT4 infection;~* liver decompensation,~* hepatocellular carcinoma,~* major severe illness, such as renal failure, congestive heart failure, thyroid dysfunction, respiratory failure, autoimmune disease and poorly controlled diabetes (HbA1C \>9)~* Participants with blood picture abnormalities, such as anemia (hemoglobin concentration of 10 g/or less) and thrombocytopenia (platelet count \<50,000 cells/mm3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF + RBV (Naive) (Type: ACTIVE_COMPARATOR): For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
- SOF + RBV (Experienced) (Type: ACTIVE_COMPARATOR): For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
- SOF + SMV (Naive) (Type: ACTIVE_COMPARATOR): For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
- SOF + SMV (Expereined) (Type: ACTIVE_COMPARATOR): For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).